Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Antimicrobial Reports"'
Autor:
Rima Snariene, Hans Georg Münch, Anne Smits, Christopher M. Rubino, Arunas Liubsys, Karine Litherland, Tomasz Tomasik, Kamal Hamed, Dace Gardovska, Chi D. Hornik, Mark J Polak, Przemko Kwinta, Veerle Cossey, Sebastian Schröpf, Christine Ruehle, Miroslava Bosheva
Publikováno v:
The Pediatric Infectious Disease Journal
Pediatric infectious disease journal, Philadelphia : Lippincott Williams and Wilkins, 2021, vol. 40, no. 11, p. 997-1003
Pediatric infectious disease journal, Philadelphia : Lippincott Williams and Wilkins, 2021, vol. 40, no. 11, p. 997-1003
Supplemental Digital Content is available in the text.
Background: Ceftobiprole, the active moiety of the prodrug ceftobiprole medocaril, is an advanced-generation, broad-spectrum, intravenous cephalosporin, which is currently approved for the t
Background: Ceftobiprole, the active moiety of the prodrug ceftobiprole medocaril, is an advanced-generation, broad-spectrum, intravenous cephalosporin, which is currently approved for the t
Autor:
Jennifer I. Smart, Éva Károly, Mikael Saulay, Agnes Nemeth, Rusudan Gujabidze, Kamal Hamed, Miroslava Bosheva
Publikováno v:
The Pediatric Infectious Disease Journal
Supplemental Digital Content is available in the text.
Background: The advanced-generation, broad-spectrum, intravenous (IV) cephalosporin, ceftobiprole, is an effective and well-tolerated treatment for adults with hospital-acquired pneumonia (H
Background: The advanced-generation, broad-spectrum, intravenous (IV) cephalosporin, ceftobiprole, is an effective and well-tolerated treatment for adults with hospital-acquired pneumonia (H
Autor:
Baker, Jeffrey, Block, Stanley L., Matharu, Balpreet, Burleigh Macutkiewicz, Laura, Wildum, Steffen, Dimonaco, Sophie, Collinson, Neil, Clinch, Barry, Piedra, Pedro A.
Publikováno v:
The Pediatric Infectious Disease Journal
Background: Baloxavir marboxil (baloxavir) is a novel, cap-dependent endonuclease inhibitor that has previously demonstrated efficacy in the treatment of influenza in adults and adolescents. We assessed the safety and efficacy of baloxavir in otherwi
Publikováno v:
The Pediatric Infectious Disease Journal
Supplemental Digital Content is available in the text.
Background: The Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) study is a nationwide longitudinal antibiotic resistance surveillance program specific to bacterial pathogen
Background: The Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) study is a nationwide longitudinal antibiotic resistance surveillance program specific to bacterial pathogen
Autor:
Tawanda Gumbo, James A Seddon, Shashikant Srivastava, Johanna S. van Zyl, Katherine Riley Martin, Jan-William Alffenaar, Kayle N Cirrincione, Tania A Thomas, Devyani Deshpande
Publikováno v:
The Pediatric Infectious Disease Journal
Background: Ceftazidime-avibactam is an effective agent for the treatment of tuberculosis (TB) but requires frequent administration because of a short half-life. Due to a longer half-life, ceftriaxone could allow intermittent dosing. Methods: First,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d917ed498ed3b45abda9e413d46a7e0
http://hdl.handle.net/10044/1/81560
http://hdl.handle.net/10044/1/81560
Autor:
Takeki Uehara, Toru Ishibashi, Kenji Tsuchiya, Hiroki Sakaguchi, Pedro A. Piedra, Takato Yokoyama, Chisako Sato, Takao Shishido
Publikováno v:
The Pediatric Infectious Disease Journal
Supplemental Digital Content is available in the text.
Background: A granule formulation of baloxavir marboxil, a selective inhibitor of influenza cap-dependent endonuclease, was newly developed for children with difficulty swallowing tablets. M
Background: A granule formulation of baloxavir marboxil, a selective inhibitor of influenza cap-dependent endonuclease, was newly developed for children with difficulty swallowing tablets. M
Autor:
Roilides, E., Carlesse, F., Tawadrous, M., Leister-Tebbe, H., Conte, U., Raber, S., Swanson, R., Yan, J. L., Aram, J. A., The Anidulafungin A8851008 Pediatric Study Group members are as follows: Natalia Dmitrieva, Queiroz-Telles F., Sandra, Arnold, Antonio, Arrieta, Fabio, Motta, Cheng-Hsun, Chiu, Gentile, Giuseppe, Chuhl Joo Lyu, Brian Patrick Lee, Vassiliki, Syriopoulou, Audra, Deveikis, Jaime, Deville, Jong Jin Seo, Irina, Shipitsina, Nelson, Horigoshi, Joan, Robinson, Richard, Grundy, William, Steinbach, Rainer, Gedeit
Publikováno v:
The Pediatric Infectious Disease Journal
Nineteen patients 1 month to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5aeae54a109e54e9274d2ad7f51a09b
http://hdl.handle.net/11573/1396098
http://hdl.handle.net/11573/1396098
Autor:
Christopher Lademacher, Deborah Jednachowski, Paolo Manzoni, David A. Kaufman, Thomas J. Walsh, Chunzhang Wu, Daniel K. Benjamin, Laura L. Kovanda, Atsunori Kaibara, P. Brian Smith, Brigit Isaacson, William W. Hope, Antonio Arrieta
Publikováno v:
PEDIATRIC INFECTIOUS DISEASE JOURNAL
The Pediatric Infectious Disease Journal
The Pediatric Infectious Disease Journal
Supplemental Digital Content is available in the text.
Background: Amphotericin B deoxycholate (AmB-D) is standard of care treatment for neonatal invasive candidiasis (IC). Micafungin (MCA) has broad-spectrum fungicidal activity against Candida
Background: Amphotericin B deoxycholate (AmB-D) is standard of care treatment for neonatal invasive candidiasis (IC). Micafungin (MCA) has broad-spectrum fungicidal activity against Candida
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6909469481bfcea20b33fa4698057989
http://livrepository.liverpool.ac.uk/3020301/1/A_Phase_3_Study_of_Micafungin_Versus_Amphotericin.96678(1).pdf
http://livrepository.liverpool.ac.uk/3020301/1/A_Phase_3_Study_of_Micafungin_Versus_Amphotericin.96678(1).pdf
Autor:
Rashidkhan Pathan, Riccardo Utili, Zoe H. Dailiana, Kamal Hamed, Nisichenko Dmitriy, Vassiliki Syriopoulou
Publikováno v:
The Pediatric Infectious Disease Journal
Gram-positive bacteria, especially methicillin-resistant Staphylococcus aureus (MRSA), are known to be common pathogens in children and adolescents in both healthcare and community-associated infections.1–3 Treatment of resistant pathogens includin
Publikováno v:
The Pediatric Infectious Disease Journal
Background: Invasive fungal infections cause excessive morbidity and mortality in premature neonates and severely ill infants. Methods: Safety and efficacy outcomes of micafungin were compared between prematurely and non-prematurely born infants